SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Journal:
Nature Medicine
Published:
DOI:
10.1038/s41591-026-04452-0
Affiliations:
24
Authors:
31
Go to article
Institutions Authors Share
AbbVie, United States of America (USA)
11.000000
11.000000
 0.35
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
 0.03
Yonsei Cancer Hospital, South Korea
1.000000
 0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
 0.03
Yale University, United States of America (USA)
1.000000
 0.03
National Cancer Center (NCC), South Korea
1.000000
 0.03
Holden Comprehensive Cancer Center, UI, United States of America (USA)
1.000000
 0.03
UH Seidman Cancer Center, CWRU, United States of America (USA)
1.000000
 0.03
Washington University in St. Louis (WUSTL), United States of America (USA)
1.000000
 0.03
South Texas Accelerated Research Therapeutics, LLC (START), United States of America (USA)
1.000000
 0.03
The University of Chicago Medicine, United States of America (USA)
1.000000
 0.03
Vall d'Hebron University Hospital (HUVH), ICS, Spain
1.000000
 0.03
CHA Bundang Medical Center, South Korea
1.000000
 0.03
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)
1.000000
 0.03
Seoul National University Hospital (SNUH), South Korea
1.000000
 0.03
Chonnam National University Hwasun Hospital (CNUHH), South Korea
1.000000
 0.03
Hanyang University Medical Center (HYUMC), South Korea
1.000000
 0.03
Hokkaido Cancer Center, Japan
1.000000
 0.03
START Midwest, United States of America (USA)
1.000000
 0.03
Chaim Sheba Medical Center at Tel HaShomer, Israel
0.500000
 0.02
Tel Aviv University (TAU), Israel
0.500000
 0.02
Hospital Universitario 12 de Octubre, Spain
0.500000
 0.02
Complutense University of Madrid (UCM), Spain
0.500000
 0.02